Cite
HARVARD Citation
Campone, M. et al. (2018). Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European journal of cancer. pp. 147-154. [Online].